Related coverage linked through entity extraction aliases.
Aug 22, 2026
Novartis has posted job openings for an Associate Expert Drug Supply in Slovenia (€20,300–€37,700), an Associate Director, Solutions Delivery Clinical Analytics in New Jersey ($180,090–$185,000), and an Associate Director, Program Launch and Change Excellence ($145,600–$270,400).
Aug 17, 2026
The WHO approved the first malaria drug for infants weighing under 5kg, and researchers unveiled a single-dose compound, cabamiquine, showing promise in early trials. Investment in the Medicines for Malaria Venture yielded $13 in health benefits per $1 invested, averting 1.6 million deaths.
Aug 10, 2026
Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
Jul 29, 2026
ChrysCapital-led open offer for Novartis India saw only 40 shares accepted. The consortium acquired Novartis AG's 70.68% stake for Rs 1,445.8 crore; public shareholding now stands at 29.32%.
Jul 21, 2026
President Trump said Novartis CEO Vas Narasimhan told him the drugmaker is building 11 U.S. plants due to tariff policies. Novartis confirmed progress on facilities in North Carolina, California, and Florida. Narasimhan also said he has no plans to step down as CEO.
May 20, 2026
Drug R&D platform markets are projected to grow through 2031, driven by AI and computational chemistry. Innovation and simulation platforms accelerate drug discovery across pharmaceutical, chemical, and medical industries.
Aug 09, 2026
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
May 28, 2026
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
Jul 10, 2026
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
Jul 23, 2026
FDA approved Novartis' Fabhalta for IgAN to slow kidney function decline. Phase III ALIGN data for Vanrafia showed ~34% slower eGFR decline vs placebo and were published in The Lancet.
Jul 07, 2026
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
Jul 22, 2026
FDA granted traditional approval to Novartis' Fabhalta (iptacopan) for IgA nephropathy. Phase 3 APPLAUSE-IgAN data showed eGFR decline slowed by 48% versus placebo over two years.
Feb 24, 2026
Real-world analyses of Novartis' Pluvicto show a median PFS of 13.5 months in taxane-naive mCRPC patients, with better outcomes when used after one ARPI. Additional data indicate subsequent therapies remain effective after Pluvicto, while a separate analysis found gaps in guideline-adherent treatment for mHSPC.
Jul 27, 2026
Novartis beat second-quarter profit expectations as Kisqali, Kesimpta and Leqvio offset a 50% plunge in Entresto sales. The Swiss drugmaker maintained its full-year guidance and awaits late-stage data on three experimental drugs.
Jul 29, 2026
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
Jul 03, 2026
China's 12th national Volume-Based Procurement round places RMB 60 billion across 65 drug varieties, accelerating generics and biosimilars substitution. Separately, Genialis launched BioBridge to help translate Chinese oncology trial results into Western development programs, as Chinese out-licensing hit $137.7 billion in 2025.
Jul 23, 2026
Cell culture media bags, medical-grade PCR packaging, cold chain packaging, and Ireland sterile injectables CDMO markets are forecast to grow through 2035-2036, with CAGRs ranging from 9.2% to 11.8%.
Aug 04, 2026
AI drug discovery is moving from hype to proof in 2026, with multi-billion-dollar partnerships, new joint initiatives, and major investments accelerating AI-native biotech pipelines and data-driven deals.
Aug 07, 2026
AI is transforming drug discovery across target ID, molecule design and trial optimization. Milestones include regulatory qualification of digital-twin controls and positive Phase 2a data, though 90-95% of candidates still fail.
Jul 27, 2026
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
